Neocryptolepine

Neocryptolepine at a Glance

Neocryptolepine — also called cryptotackieine — is one of the indoloquinoline alkaloids of Cryptolepis sanguinolenta, the scrambling West African shrub (“Ghana quinine”) whose root decoction is a traditional antimalarial. It is a minor constituent of that root; the closely related cryptolepine is the dominant, most-studied alkaloid.

Structurally, neocryptolepine is the linear isomer of cryptolepine: both are methylated tetracyclic indoloquinolines, but the ring nitrogens sit in different positions, and that single change lowers neocryptolepine’s affinity for DNA and softens most of its activities relative to its more potent sibling ^{2Reference 2Bailly C et al. · 2000DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepineView study →}.

Its interest is almost entirely preclinical and chemical. As an isolated molecule it intercalates DNA, interferes with topoisomerase II, and shows in-vitro antimalarial, anticancer and antibacterial activity ^{1,2,4Reference 1Cimanga K et al. · 1997In vitroIn vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolentaView study →Reference 2Bailly C et al. · 2000DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepineView study →Reference 4Cimanga K et al. · 1998Antibacterial and antifungal activities of neocryptolepine, biscryptolepine and cryptoquindoline, alkaloids isolated from Cryptolepis sanguinolentaView study →}. But there is no human use, no clinical trial, and the standout in-vivo antimalarial results in this family belong to synthetic derivatives, not to the natural alkaloid itself ^{5Reference 5Van Miert S et al. · 2004In vitroIn vitro inhibition of beta-haematin formation, DNA interactions, antiplasmodial activity, and cytotoxicity of synthetic neocryptolepine derivativesView study →}. It is best read as a lead scaffold — a comparatively less-cytotoxic template that medicinal chemists build on — rather than a therapy.

Neocryptolepine vs. Cryptolepine

The single most important fact about this molecule is that it is an isomer of the flagship alkaloid, and the two are routinely confused.

• Cryptolepine is 5-methyl-10H-indolo[3,2-b]quinoline — the angular, dominant, more potent alkaloid.
• Neocryptolepine is 5-methyl-5H-indolo[2,3-b]quinoline — the linear isomer, in which the indole unit is rotated relative to the quinoline so the two nitrogens lie on the same side of the chromophore ^{2,6Reference 2Bailly C et al. · 2000DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepineView study →Reference 6Lavrado J et al. · 2010Indoloquinolines as scaffolds for drug discoveryView study →}.

That geometric difference has real pharmacological consequences. Neocryptolepine still intercalates DNA (preferentially at GC-rich sequences) and still interferes with topoisomerase II, but with reduced DNA affinity and correspondingly weaker effects — in matched leukaemia assays cryptolepine was about four times more cytotoxic than neocryptolepine ^{2,3Reference 2Bailly C et al. · 2000DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepineView study →Reference 3Dassonneville L et al. · 2000Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosisView study →}. A third natural isomer, isocryptolepine (cryptosanguinolentine), completes the set of positional variants from the same plant.

For drug discovery this “weaker” profile is not purely a downside: neocryptolepine’s lower baseline cytotoxicity has made it an attractive scaffold to derivatise, aiming for compounds that keep the antimalarial or antitumour activity while widening the gap from host-cell toxicity ^{5Reference 5Van Miert S et al. · 2004In vitroIn vitro inhibition of beta-haematin formation, DNA interactions, antiplasmodial activity, and cytotoxicity of synthetic neocryptolepine derivativesView study →}.

What It's Used For

Neocryptolepine’s evidence is narrow and preclinical: a handful of in-vitro studies on the isolated alkaloid across three activities, plus a large synthetic-analogue literature that must be kept separate from the natural molecule.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here is in-vitro isolate data, so the ceiling is low; read the per-row basis.

01Anticancer / cytotoxic (DNA & topoisomerase II)Promising46%Two mechanistic in-vitro studies on the isolate; ~4× weaker than cryptolepine ^{2,3Reference 2Bailly C et al. · 2000DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepineView study →Reference 3Dassonneville L et al. · 2000Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosisView study →}

02Antiplasmodial / antimalarialShaky41%In-vitro activity vs chloroquine-resistant P. falciparum ^{1,6Reference 1Cimanga K et al. · 1997In vitroIn vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolentaView study →Reference 6Lavrado J et al. · 2010Indoloquinolines as scaffolds for drug discoveryView study →}; in-vivo gains belong to synthetic derivatives ^{5Reference 5Van Miert S et al. · 2004In vitroIn vitro inhibition of beta-haematin formation, DNA interactions, antiplasmodial activity, and cytotoxicity of synthetic neocryptolepine derivativesView study →}

03Antibacterial / antifungalShaky27%Bacteriostatic vs gram-positive bacteria; weak Candida inhibition ^{4Reference 4Cimanga K et al. · 1998Antibacterial and antifungal activities of neocryptolepine, biscryptolepine and cryptoquindoline, alkaloids isolated from Cryptolepis sanguinolentaView study →}

Mechanisms

The load-bearing point is the isomerism: neocryptolepine’s rotated indole lowers its DNA affinity, which is why the same mechanisms operate at roughly a quarter of cryptolepine’s cytotoxic potency ^{2,3Reference 2Bailly C et al. · 2000DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepineView study →Reference 3Dassonneville L et al. · 2000Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosisView study →}.

Pharmacokinetics

There is no dedicated human or animal pharmacokinetic dataset for neocryptolepine. The governing liability for the whole indoloquinoline class is poor aqueous solubility, which hampers bioavailability and is repeatedly named as the reason these alkaloids have not advanced to clinical development ^{6Reference 6Lavrado J et al. · 2010Indoloquinolines as scaffolds for drug discoveryView study →} — much of the medicinal-chemistry effort on the scaffold is aimed at fixing exactly this. Absorption, distribution, metabolism (CYP involvement), active metabolites and half-life for the natural molecule are all uncharacterised. Any potency read off an in-vitro assay should be discounted accordingly.

Clinical Trials

There are no clinical trials of neocryptolepine. All human-relevant interest is preclinical and, for in-vivo work, largely centred on synthetic derivatives rather than the natural alkaloid.

Last checked: July 2026.

Isolate vs. Plant Studies

This molecule sits firmly on the isolate side. Every neocryptolepine finding above comes from the purified alkaloid tested in vitro — DNA-binding and topoisomerase assays ^{2Reference 2Bailly C et al. · 2000DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepineView study →}, leukaemia-cell cytotoxicity ^{3Reference 3Dassonneville L et al. · 2000Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosisView study →}, antiplasmodial screens ^{1Reference 1Cimanga K et al. · 1997In vitroIn vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolentaView study →}, and antimicrobial MICs ^{4Reference 4Cimanga K et al. · 1998Antibacterial and antifungal activities of neocryptolepine, biscryptolepine and cryptoquindoline, alkaloids isolated from Cryptolepis sanguinolentaView study →}. None of it is whole-plant work. The traditional preparation is a water decoction of the whole Cryptolepis sanguinolenta root, whose activity is dominated by the far more abundant cryptolepine ^{1,6,7Reference 1Cimanga K et al. · 1997In vitroIn vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolentaView study →Reference 6Lavrado J et al. · 2010Indoloquinolines as scaffolds for drug discoveryView study →Reference 7Osafo N et al. · 2017ReviewPhytochemical and pharmacological review of Cryptolepis sanguinolenta (Lindl.) SchlechterView study →}; because neocryptolepine is only a trace component of that root, the herb’s antimalarial reputation cannot be attributed to it. So the usual caveat is inverted here — the concern is not “does the isolate reflect the plant?” but “this minor isolate is not what the plant is doing.”

Prevalence in Nature

Neocryptolepine is a minor alkaloid of the root and root bark of Cryptolepis sanguinolenta (Apocynaceae/Periplocaceae), a thin-stemmed climbing shrub of West and Central Africa used traditionally for malaria, diarrhoea and respiratory complaints ^{7Reference 7Osafo N et al. · 2017ReviewPhytochemical and pharmacological review of Cryptolepis sanguinolenta (Lindl.) SchlechterView study →}. Within the root’s indoloquinoline fraction it is a trace constituent, greatly outweighed by cryptolepine, which is the alkaloid that has been quantified and agronomically optimised; neocryptolepine’s own concentration has not been separately quantified in the literature ^{4,6,7Reference 4Cimanga K et al. · 1998Antibacterial and antifungal activities of neocryptolepine, biscryptolepine and cryptoquindoline, alkaloids isolated from Cryptolepis sanguinolentaView study →Reference 6Lavrado J et al. · 2010Indoloquinolines as scaffolds for drug discoveryView study →Reference 7Osafo N et al. · 2017ReviewPhytochemical and pharmacological review of Cryptolepis sanguinolenta (Lindl.) SchlechterView study →}. It belongs to the same structural family as the plant’s other indoloquinolines — cryptolepine, isocryptolepine, quindoline, and the dimeric biscryptolepine and cryptoquindoline with which it was co-isolated ^{4Reference 4Cimanga K et al. · 1998Antibacterial and antifungal activities of neocryptolepine, biscryptolepine and cryptoquindoline, alkaloids isolated from Cryptolepis sanguinolentaView study →}. Because no measured figure exists for this molecule, no “Content by Source” chart is shown; the missing quantitation is logged as a gap.

Discovery & Synthesis

Neocryptolepine was first isolated in 1996 from the root bark of Cryptolepis sanguinolenta — and, in a coincidence typical of natural-product chemistry, by two groups at once. Cimanga and co-workers isolated the cryptolepine isomer in which both nitrogens sit on the same side of the ring system and named it neocryptolepine; simultaneously Sharaf and colleagues characterised the same 5-methyl-5H-indolo[2,3-b]quinoline and christened it cryptotackieine ^{6,7Reference 6Lavrado J et al. · 2010Indoloquinolines as scaffolds for drug discoveryView study →Reference 7Osafo N et al. · 2017ReviewPhytochemical and pharmacological review of Cryptolepis sanguinolenta (Lindl.) SchlechterView study →}. Both names remain in use for the identical molecule.

Because it is a compact, planar heterocycle, neocryptolepine quickly became a popular synthetic target, and several total and formal syntheses of the indolo[2,3-b]quinoline core have been published — the same routes medicinal chemists use to make the substituted analogues that carry most of the family’s in-vivo promise ^{5,6Reference 5Van Miert S et al. · 2004In vitroIn vitro inhibition of beta-haematin formation, DNA interactions, antiplasmodial activity, and cytotoxicity of synthetic neocryptolepine derivativesView study →Reference 6Lavrado J et al. · 2010Indoloquinolines as scaffolds for drug discoveryView study →}. Any commercial neocryptolepine is therefore a made molecule (a research reagent), not a plant extract; the natural material is present at too low a level in the root to serve as a practical source.

Patents: not yet researched.

Toxicity & Safety

Neocryptolepine carries a moderate flag. It is a DNA-intercalating, topoisomerase-II-interfering cytotoxin — genotoxic-type mechanisms — and is directly cytotoxic to mammalian cell lines in vitro ^{2,3Reference 2Bailly C et al. · 2000DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepineView study →Reference 3Dassonneville L et al. · 2000Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosisView study →}. The badge is moderate rather than higher because its DNA affinity and cytotoxic potency are markedly lower than cryptolepine’s (about four-fold in matched assays) ^{3Reference 3Dassonneville L et al. · 2000Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosisView study →}; it is not low, because a compound whose principal actions are DNA intercalation and topoisomerase interference cannot be treated as benign. Note that there is no formal safety, genotoxicity or repeat-dose toxicology package for the isolated molecule, and no human data at all — the flag is inferred from its mechanism and in-vitro cytotoxicity, not from a safety study.

Safety at a Glance

⚠️ Moderate toxicity

• DNA-directed cytotoxin. Intercalates DNA and interferes with topoisomerase II; cytotoxic to mammalian cells in vitro — treat as a genotoxic-class research chemical, not a supplement.
• No safety data. No genotoxicity, reproductive or repeat-dose toxicology and no human exposure data exist for the isolated alkaloid.
• Lower potency than cryptolepine. Its reduced DNA affinity makes it roughly four-fold less cytotoxic than its sibling isomer in matched assays — part of why it is studied as a scaffold.
• Not the plant’s active. Do not read Cryptolepis traditional-use safety onto this trace isolate; the herb’s dominant alkaloid is cryptolepine.

Dosage

There is no dose. Neocryptolepine is a research molecule with no approved or traditional use as an isolated compound; it has never been dosed in humans, and its poor aqueous solubility has kept it out of clinical development ^{6Reference 6Lavrado J et al. · 2010Indoloquinolines as scaffolds for drug discoveryView study →}. The concentrations in the literature are in-vitro assay concentrations (typically low micromolar) used to characterise DNA binding, cytotoxicity and antiplasmodial activity of the purified alkaloid ^{1,2,3Reference 1Cimanga K et al. · 1997In vitroIn vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolentaView study →Reference 2Bailly C et al. · 2000DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepineView study →Reference 3Dassonneville L et al. · 2000Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosisView study →} — laboratory figures, not a personal recommendation. Human exposure, such as it is, occurs only as a trace component of whole Cryptolepis sanguinolenta root preparations, which are standardised (if at all) to cryptolepine, not to this molecule ^{7Reference 7Osafo N et al. · 2017ReviewPhytochemical and pharmacological review of Cryptolepis sanguinolenta (Lindl.) SchlechterView study →}.

References

1. Cimanga K, De Bruyne T, Pieters L, Vlietinck AJ, Turger CA (1997). In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/9249972/
2. Bailly C, Laine W, Baldeyrou B, De Pauw-Gillet MC, Colson P, Houssier C, Cimanga K, Van Miert S, Vlietinck AJ, Pieters L (2000). DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepine. Anti-Cancer Drug Design. https://pubmed.ncbi.nlm.nih.gov/11049087/
3. Dassonneville L, Lansiaux A, Wattelet A, Wattez N, Mahieu C, Van Miert S, Pieters L, Bailly C (2000). Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosis. European Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/11099695/
4. Cimanga K, De Bruyne T, Pieters L, Totté J, Tona L, Kambu K, Vanden Berghe D, Vlietinck AJ (1998). Antibacterial and antifungal activities of neocryptolepine, biscryptolepine and cryptoquindoline, alkaloids isolated from Cryptolepis sanguinolenta. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/23195843/
5. Van Miert S, Jonckers T, Cimanga K, Maes L, Maes B, Lemière G, Dommisse R, Vlietinck A, Pieters L (2004). In vitro inhibition of beta-haematin formation, DNA interactions, antiplasmodial activity, and cytotoxicity of synthetic neocryptolepine derivatives. Experimental Parasitology. https://pubmed.ncbi.nlm.nih.gov/15582513/
6. Lavrado J, Moreira R, Paulo A (2010). Indoloquinolines as scaffolds for drug discovery. Current Medicinal Chemistry. https://pubmed.ncbi.nlm.nih.gov/20491639/
7. Osafo N, Mensah KB, Yeboah OK (2017). Phytochemical and pharmacological review of Cryptolepis sanguinolenta (Lindl.) Schlechter. Advances in Pharmacological Sciences. https://pubmed.ncbi.nlm.nih.gov/29750083/

View all 7 references▾